Brown P, Pieters R, Biondi A. How I treat infant leukemia. Blood. 2019;133:205–14.

Article  CAS  PubMed  Google Scholar 

Katsanis E, Sapp LN, Reid SC, Reddivalla N, Stea B. T-cell replete myeloablative haploidentical bone marrow transplantation is an effective option for pediatric and young adult patients with high-risk hematologic malignancies. Front Pediatr. 2020;8:282.

Article  PubMed  PubMed Central  Google Scholar 

Truscott L, Pariury H, Hanmod S, Davini M, de la Maza M, Sapp LN, et al. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation. Pediatr Blood Cancer. 2023;70:e30102.

Article  CAS  PubMed  Google Scholar 

Katsanis E, Stea B, Kovacs K, Truscott L, Husnain M, Khurana S, et al. Feasibility and efficacy of partially replacing post-transplantation cyclophosphamide with bendamustine in pediatric and young adult patients undergoing haploidentical bone marrow transplantation. Transplant Cell Ther. 2022;28:390.e1–e10.

Article  CAS  PubMed  Google Scholar 

Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide/bendamustine in pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant. 2018;24:2034–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato M, Hasegawa D, Koh K, Kato K, Takita J, Inagaki J, et al. Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation. Br J Haematol. 2015;168:564–70.

Article  PubMed  Google Scholar 

Ochoa-Fernandez B, Galan-Gomez V, Guerra-Garcia P, Sanroman S, Martinez I, Bueno D, et al. Younger age and induction failure predict outcomes in infant leukemia: 30 years of experience in a tertiary center. Front Pediatr. 2023;11:1166176.

Article  PubMed  PubMed Central  Google Scholar 

Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53:138–45.

Article  CAS  PubMed  Google Scholar 

Philippe M, Neely M, Rushing T, Bertrand Y, Bleyzac N, Goutelle S. Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. Bone Marrow Transplant. 2019;54:448–57.

Article  CAS  PubMed  Google Scholar 

Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3:e526–36.

Article  PubMed  PubMed Central  Google Scholar 

Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, et al. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood Adv. 2021;5:2106–14.

Article  CAS  PubMed  Google Scholar 

Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020;135:1049–57.

PubMed  PubMed Central  Google Scholar